[EN] SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS<br/>[FR] PYRIMIDINYL-AMINES SUBSTITUÉES EN TANT QU'INHIBITEURS DE LA PROTÉINE KINASE
申请人:SCRIPPS RESEARCH INST
公开号:WO2009032861A1
公开(公告)日:2009-03-12
The present invention provides novel substituted pyrimidinyl-amines that are useful as inhibitors of protein kinases, especially c-Jun N-terminal kinases (JNK) and pharmaceutical compositions thereof and methods of using the same for treating conditions responsive to the inhibition of the JNK pathway.
SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS
申请人:Kamenecka Theodore Mark
公开号:US20130231336A1
公开(公告)日:2013-09-05
The present invention provides novel substituted pyrimidinyl-amines that are useful as inhibitors of protein kinases, especially c-Jun N-terminal kinases (JNK) and pharmaceutical compositions thereof and methods of using the same for treating conditions responsive to the inhibition of the JNK pathway.
Design, Synthesis and Discovery of Picomolar Selective α4β2 Nicotinic Acetylcholine Receptor Ligands
作者:Venkata M. Yenugonda、Yingxian Xiao、Edward D. Levin、Amir H. Rezvani、Thao Tran、Nour Al-Muhtasib、Niaz Sahibzada、Teresa Xie、Corinne Wells、Susan Slade、Joshua E. Johnson、Sivanesan Dakshanamurthy、Hye-Sik Kong、York Tomita、Yong Liu、Mikell Paige、Kenneth J. Kellar、Milton L. Brown
DOI:10.1021/jm4008455
日期:2013.11.14
Developing novel and selective compounds that desensitize alpha 4 beta 2 nicotinic acetylcholine receptors (nAChRs) could provide new effective treatments for nicotine addiction, as well as other disorders. Here we report a new class of nAChR ligands that display high selectivity and picomolar binding affinity for alpha 4 beta 2 nicotinic receptors. The novel compounds have K-i; values in the range of 0.031-0.26 nM and properties that should make them good candidates as drugs acting in the CNS. The selected lead compound 1 (VMY-2-95) binds with high affinity and potently desensitizes alpha 4 beta 2 nAChRs. At a dose of 3 mg/kg, compound 1 significantly reduced rat nicotine self-administration. The overall results support further characterizations of compound 1 and its analogues in preclinical models of nicotine addiction and perhaps other disorders involving nAChRs.